BioSpace News Archive

ChemImage, a leader in molecular chemical imaging technology, is pleased to announce that the Binational Industrial Research & Development Foundation is investing $950,000 to develop NurseSpace, an innovative medication identification and dispensing system.

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer.

BioInvent International today resolved to elect Natalie Berner and Nanna Luneborg as new Board members.

NAPIGEN, a company developing proprietary technology to edit mitochondrial and chloroplast genomes, completed a $7.85 million seed funding round.

BioCardia ® , Inc. [Nasdaq: BCDA], Sunnyvale, Calif. – BioCardia ® , Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Company’s CEO Peter Altman has been invited to participate at two upcoming therapeutic development symposia.

Ancora Heart Receives Breakthrough Device Designation from FDA for the AccuCinch ® Ventricular Restoration System.

Worldwide Clinical Trials, Inc. (Worldwide), the industry’s leading global, midsize, full-service contract research organization (CRO), today announced its strategic partnership with Invitae, a leading medical genetics company.

Kiromic BioPharma, Inc. (NASDAQ: KRBP) (“Kiromic” or the “Company”), a clinical-stage fully integrated biotherapeutics company using its proprietary DIAMOND ® artificial intelligence and data mining platform to develop cell and gene therapies with a focus on immuno-oncology, announces the appointment of Leonardo Mirandola, Ph.D., as Chief Scientific Officer, effective immediately.

Bayer announced today that prescription-strength Astepro® Allergy (Azelastine HCI .15%) is now available over-the-counter (OTC) in retail stores nationwide.

Allogene Therapeutics, Inc. announced the appointment of Stephen L. Mayo, Ph.D., a world renowned expert in computational protein design, to the company’s Board of Directors.